News from sorrento therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 12, 2015, 09:00 ET
Sorrento Therapeutics, Inc.

Sorrento Provides Status Update on the Cynviloq™ Registrational TRIBECA™ Study

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced...

Jan 06, 2015, 09:00 ET
Sorrento Therapeutics, Inc.

Conkwest, Sorrento And NantWorks Announce Presentation At The 33rd Annual J. P. Morgan Healthcare Conference By Dr. Patrick Soon-Shiong

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and Conkwest, Inc., an...

Jan 05, 2015, 09:00 ET

Sorrento To Present At The 2015 Biotech Showcase And 8th Annual OneMedForum In San Francisco

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and...

Dec 24, 2014, 08:00 ET

Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board

 Conkwest, Inc., the Natural Killer Cell Company of the West, developing the proprietary Natural Killer (NK) cell-line platform,...

Dec 19, 2014, 06:00 ET

Sorrento and Conkwest Announce Exclusive Global Collaboration

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE;  Sorrento), an oncology company developing new treatments for cancer and associated pain, and...

Dec 15, 2014, 09:25 ET

Sorrento Announces Strategic Investment By And Collaboration With Nantworks Founder Dr. Patrick Soon-Shiong For The Advancement Of Cancer Immunotherapies

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today...

Dec 08, 2014, 09:15 ET

Sorrento Therapeutics Announces Poster Presentations on its Anti-c-Met/PD-L1 Bispecific Antibodies and Anti-c-Met-Antibody Drug Conjugate at the 37th Annual San Antonio Breast Cancer Symposium

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated...

Dec 03, 2014, 09:30 ET

Sorrento To Present At The 2014 Oppenheimer Healthcare Conference

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced...

Nov 12, 2014, 11:00 ET

Sorrento To Present At The 2014 Stifel Healthcare Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), today announced that Dr. Henry Ji, President and Chief Executive Officer, will present...

Oct 16, 2014, 06:27 ET

Los datos del estudio TRIBECA apoyan el potencial de la bioequivalencia entre Cynviloq y paclitaxel

- Los datos farmacocinéticos iniciales del estudio TRIBECA apoyan el potencial de la bioequivalencia entre Cynviloq y paclitaxel...

Oct 15, 2014, 16:17 ET

Les données pharmacocinétiques initiales de l'étude TRIBECA confirment le potentiel de bioéquivalence entre Cynviloq et le paclitaxel lié à de l'albumine

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), une société de produits oncologiques développant de nouveaux traitements...

Oct 15, 2014, 07:55 ET

Erste pharmakokinetische Daten aus TRIBECA-Studie stützen potenzielle Bioäquivalenz zwischen Cynviloq und Albumin-gebundenem Paclitaxel

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), ein Onkologieunternehmen, das neue Behandlungsmethoden für Krebs sowie für die...

Oct 14, 2014, 16:00 ET

Initial Pharmacokinetic Data From TRIBECA Study Support Potential For Bioequivalence Between Cynviloq And Albumin-Bound Paclitaxel

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain,...

Oct 03, 2014, 14:41 ET

Sorrento and Lee's Pharmaceutical Enter into Exclusive China Licensing Agreement to Develop and Commercialize Anti-PD-L1 antibody

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Sep 05, 2014, 08:45 ET

Sorrento Therapeutics to Present at Two Healthcare Conferences

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Aug 26, 2014, 08:45 ET

Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Aug 18, 2014, 07:45 ET

Data Published by Researchers from The Scripps Research Institute Demonstrate Potential for MYC Inhibitor Licensed by Sorrento Therapeutics

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Aug 08, 2014, 17:00 ET

Sorrento Therapeutics Appoints Douglas Ebersole to its Board of Directors

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...

Jul 31, 2014, 17:38 ET

Sorrento Announces the Unexpected Death of its Chief Business Officer

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) today announced the death of Mr. Amar Singh, Chief Business Officer and Executive Vice...

Jul 21, 2014, 08:45 ET

Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its...